Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt last quarter as it became available in more ...

Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...

Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead ... with the potential for tolerability that is likely to be in the range of Wegovy and Zepbound’s approved labels, and ...

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its ...